WO2003014303A3 - Molecular interactions in cells - Google Patents

Molecular interactions in cells Download PDF

Info

Publication number
WO2003014303A3
WO2003014303A3 PCT/US2002/024655 US0224655W WO03014303A3 WO 2003014303 A3 WO2003014303 A3 WO 2003014303A3 US 0224655 W US0224655 W US 0224655W WO 03014303 A3 WO03014303 A3 WO 03014303A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
molecular interactions
interactions
variety
methods
Prior art date
Application number
PCT/US2002/024655
Other languages
French (fr)
Other versions
WO2003014303A2 (en
Inventor
Peter S Lu
Joshua D Rabinowitz
Johannes Schweizer
Deanna Marie Carrick
Original Assignee
Arbor Vita Corp
Peter S Lu
Joshua D Rabinowitz
Johannes Schweizer
Deanna Marie Carrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02756934A priority Critical patent/EP1443951A4/en
Priority to CA002457424A priority patent/CA2457424A1/en
Priority to AU2002321903A priority patent/AU2002321903A1/en
Priority to US10/485,788 priority patent/US20050282743A1/en
Application filed by Arbor Vita Corp, Peter S Lu, Joshua D Rabinowitz, Johannes Schweizer, Deanna Marie Carrick filed Critical Arbor Vita Corp
Publication of WO2003014303A2 publication Critical patent/WO2003014303A2/en
Priority to US10/630,590 priority patent/US7312041B2/en
Publication of WO2003014303A3 publication Critical patent/WO2003014303A3/en
Priority to US10/684,796 priority patent/US20050019841A1/en
Priority to US10/714,537 priority patent/US20060148711A1/en
Priority to AU2003291558A priority patent/AU2003291558B2/en
Priority to US10/789,102 priority patent/US20040229298A1/en
Priority to US11/053,076 priority patent/US20050255460A1/en
Priority to US11/403,141 priority patent/US20070099199A1/en
Priority to US11/650,455 priority patent/US8048676B2/en
Priority to US11/881,724 priority patent/US7972774B2/en
Priority to US11/833,848 priority patent/US20090075377A1/en
Priority to US12/606,905 priority patent/US20100120700A1/en
Priority to US12/779,501 priority patent/US20110039758A1/en
Priority to US13/212,991 priority patent/US20120052484A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in cells, particularly interactions between a PDZ protein and a PL protein. Reagents and methods that are provided are useful for treatment of a variety of diseases and conditions in a variety of cell types.
PCT/US2002/024655 1999-05-14 2002-08-02 Molecular interactions in cells WO2003014303A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
EP02756934A EP1443951A4 (en) 2001-08-03 2002-08-02 Molecular interactions in cells
CA002457424A CA2457424A1 (en) 2001-08-03 2002-08-02 Molecular interactions in cells
AU2002321903A AU2002321903A1 (en) 2001-08-03 2002-08-02 Molecular interactions in cells
US10/485,788 US20050282743A1 (en) 2001-08-03 2002-08-02 Molecular interactions in cells
US10/630,590 US7312041B2 (en) 2001-02-16 2003-07-29 Methods of diagnosing cervical cancer
US10/684,796 US20050019841A1 (en) 1999-05-14 2003-10-14 Modulation of signaling pathways
US10/714,537 US20060148711A1 (en) 1999-05-14 2003-11-14 Molecular interactions in neurons
AU2003291558A AU2003291558B2 (en) 2001-08-03 2003-11-14 Molecular interactions in neurons
US10/789,102 US20040229298A1 (en) 2000-11-11 2004-02-27 Methods and compositions for treating cervical cancer
US11/053,076 US20050255460A1 (en) 2000-11-11 2005-02-07 Methods of diagnosing cervical cancer
US11/403,141 US20070099199A1 (en) 2000-11-11 2006-04-11 Methods and compositions for treating cervical cancer
US11/650,455 US8048676B2 (en) 2000-11-11 2007-01-05 Systems of diagnosing cervical cancer
US11/881,724 US7972774B2 (en) 2001-02-16 2007-07-27 Methods of diagnosing cervical cancer
US11/833,848 US20090075377A1 (en) 2001-08-03 2007-08-03 Molecular interactions in cells
US12/606,905 US20100120700A1 (en) 2000-11-11 2009-10-27 Methods and compositions for treating cervical cancer
US12/779,501 US20110039758A1 (en) 1999-05-14 2010-05-13 Molecular Interactions in Neurons
US13/212,991 US20120052484A1 (en) 2001-02-16 2011-08-18 Methods of diagnosing cervical cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30984101P 2001-08-03 2001-08-03
US60/309,841 2001-08-03
US36006102P 2002-02-25 2002-02-25
US60/360,061 2002-02-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/080,273 Continuation-In-Part US20030049695A1 (en) 1999-05-14 2002-02-19 PDZ domain interactions and lipid rafts

Related Child Applications (7)

Application Number Title Priority Date Filing Date
US10/630,590 Continuation-In-Part US7312041B2 (en) 2000-11-11 2003-07-29 Methods of diagnosing cervical cancer
US10/684,796 Continuation-In-Part US20050019841A1 (en) 1999-05-14 2003-10-14 Modulation of signaling pathways
US10/714,537 Continuation-In-Part US20060148711A1 (en) 1999-05-14 2003-11-14 Molecular interactions in neurons
US10/789,102 Continuation-In-Part US20040229298A1 (en) 2000-11-11 2004-02-27 Methods and compositions for treating cervical cancer
US11/053,076 Continuation-In-Part US20050255460A1 (en) 2000-11-11 2005-02-07 Methods of diagnosing cervical cancer
US11/650,455 Continuation-In-Part US8048676B2 (en) 2000-11-11 2007-01-05 Systems of diagnosing cervical cancer
US11/833,848 Continuation US20090075377A1 (en) 2001-08-03 2007-08-03 Molecular interactions in cells

Publications (2)

Publication Number Publication Date
WO2003014303A2 WO2003014303A2 (en) 2003-02-20
WO2003014303A3 true WO2003014303A3 (en) 2003-08-14

Family

ID=26977039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024655 WO2003014303A2 (en) 1999-05-14 2002-08-02 Molecular interactions in cells

Country Status (4)

Country Link
EP (1) EP1443951A4 (en)
AU (1) AU2002321903A1 (en)
CA (1) CA2457424A1 (en)
WO (1) WO2003014303A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
EP1531842A4 (en) 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc Regulation of cell growth by muc1
AU2003291558B2 (en) * 2001-08-03 2009-08-13 Arbor Vita Corporation Molecular interactions in neurons
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
WO2004076646A2 (en) * 2003-02-27 2004-09-10 Arbor Vita Corporation Methods and compositions for treating cervical cancer
KR20060037244A (en) * 2003-05-02 2006-05-03 스코티쉬 바이오메디컬 리미티드 Regulation of guanine nucleotide exchange factor for a protein belonging to the rap family of small gtpases
WO2004108142A2 (en) * 2003-06-06 2004-12-16 The University Of Manchester Inhibitors of tip-1 for treatment tissue damage
CA2533789C (en) 2003-07-30 2013-09-17 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Epha2 t-cell epitope agonists and uses therefor
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
CA2551560A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
EP1709084A4 (en) * 2003-12-23 2008-05-28 Nono Inc Polypeptides for modulating binding of trp channel proteins and trp-associated proteins
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
CA2587985C (en) * 2004-11-24 2016-05-10 Neopro Labs, Llc Peptides for use in treatment in fever or pain
NZ556541A (en) * 2004-12-21 2011-01-28 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration using polypetide sequences from an alpha connexin
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
DE102005022182A1 (en) * 2005-05-09 2006-11-16 Combinature Biopharm Ag Modulators of the PDZ domain
EP1915621A2 (en) * 2005-07-01 2008-04-30 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of viral and bacterial infections
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8633160B2 (en) 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
EP2320927B1 (en) 2008-07-09 2015-06-10 University of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
CA2866115C (en) 2012-03-01 2020-03-24 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2015017034A1 (en) * 2013-08-02 2015-02-05 Gourdie Robert G Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
EP3074030A4 (en) * 2013-11-26 2017-08-16 Trustees of Dartmouth College Method for mitigating or alleviating synaptic and cognitive deficits
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
JP7002788B2 (en) * 2017-07-05 2022-03-03 拜西欧斯（北京）生物技術有限公司 Pharmaceutically acceptable salts of polypeptides and their use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976819A (en) * 1995-11-21 1999-11-02 National Jewish Medical And Research Center Product and process to regulate actin polymerization in T lymphocytes
WO2000069896A2 (en) * 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in haematopoietic cells
US20020058607A1 (en) * 1996-07-22 2002-05-16 Takaaki Sato Compounds that inhibit the interaction between signal-transducing proteins and the glgf (pdz/dhr) domain and uses thereof
US20020147306A1 (en) * 1998-11-20 2002-10-10 Danny Lin Peptides that modulate the interaction of B class ephrins and PDZ domains

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976819A (en) * 1995-11-21 1999-11-02 National Jewish Medical And Research Center Product and process to regulate actin polymerization in T lymphocytes
US20020058607A1 (en) * 1996-07-22 2002-05-16 Takaaki Sato Compounds that inhibit the interaction between signal-transducing proteins and the glgf (pdz/dhr) domain and uses thereof
US20020147306A1 (en) * 1998-11-20 2002-10-10 Danny Lin Peptides that modulate the interaction of B class ephrins and PDZ domains
WO2000069896A2 (en) * 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in haematopoietic cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOYLE ET AL., CELL, vol. 85, June 1996 (1996-06-01), pages 1067 - 1076, XP002196674 *
See also references of EP1443951A4 *
SONGYANG ET AL., SCIENCE, vol. 275, January 1997 (1997-01-01), pages 73 - 77, XP000887129 *

Also Published As

Publication number Publication date
AU2002321903A1 (en) 2003-02-24
CA2457424A1 (en) 2003-02-20
EP1443951A4 (en) 2006-05-03
EP1443951A2 (en) 2004-08-11
WO2003014303A2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
WO2003014303A3 (en) Molecular interactions in cells
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
WO2004062475A3 (en) Fluorescent assays for protein kinases
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2002079491A3 (en) Method for correlating gene expression profiles with protein expression profiles
WO2002042422A3 (en) Molecular interactions in hematopoietic cells
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
AU2002213450A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002239256A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2002031512A3 (en) Molecular interactions in hematopoietic cells
AU2002364691A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002018575A3 (en) Genes expressed in the cell cycle
AU2002258630A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2001290872A1 (en) Isolated human kinase proteins, nucleic acid molecules and uses thereof
WO2000069898A3 (en) Molecular interactions in allergy cells
AU2002258617A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2002250346A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2002356494A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2002257075A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002303137A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2005043170A3 (en) Ubiquitin-based protein interaction assays and related compositions
AU2001292647A1 (en) Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof
WO2005017109A3 (en) Nucleic acids and polypeptides required for cell survival in the absence of rb
AU2002234023A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002307033A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NO NZ OM PH PT RO RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10714537

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2457424

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002756934

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10485788

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002756934

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10714537

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11650455

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11650455

Country of ref document: US